Human Rabies – An Interview with Peter J. Costa MPH
Rabies Immune Globulin Brand Director at Kedrion Biopharma
Global Maternal Health Milestone Reached: 50th Anniversary
U.S. Approval of RhoGAM®, Rho(D) Immune Globulin
KEDRAB™: Pivotal Phase 2/3 Data presented at RITA Conference
Kedrion Biopharma and Kamada Received FDA Approval of the Product in Q3 2017
Kedrion Biopharma and Kamada Receive FDA Approval of KEDRAB™
For Post-Exposure Prophylaxis Against Rabies Infection
Kedrion Biopharma volunteers at City Rescue Mission in Jacksonville, FL
US Sales & Marketing Team joined a CSR event engaging with students from CRM’s LifeBuilder program
BIVIGAM® will no longer be available for sale or distribution in 2017
Distribution agreement between Biotest and Kedrion Biopharma has been terminated
KEDPLASMA Advances Long-Range Growth Plan
KEDPLASMA acquires 2 FDA-licensed and EU-certified plasma collection centers from IMMUNOTEK
Kedrion Biopharma attends ASHP 2016 midyear clinical meeting
Kedrion Biopharma has recognized the changing role of pharmacists in the decision-making process
Kedrion Biopharma and Kamada Announce FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin as a Post-Exposure Treatment
FDA has accepted for review a BLA for a human anti-rabies immunoglobulin (IgG) therapy
Kedrion Biopharma set for strong presence at 2016 IgNS Meeting
Kedrion Biopharma will be a bronze sponsor at the Immunoglobulin National Society (IgNS) 2016 5th National Conference